Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.70 |
| ▸ | RARG | P13631 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615497 | 0.85 | PPARG (0.54) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL7052472 | 0.82 | PPARG (1.00) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL2355017 | 0.82 | PPARG (1.00) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL11957687 | 0.82 | PPARG (1.00) | PPARGRARGRXRAMAPTALDH1A1 | |
| SCHEMBL13422203 | 0.82 | PPARG (0.71) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL5169 | 0.82 | PPARG (1.00) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL29530259 | 0.82 | PPARG (1.00) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL14383595 | 0.82 | PPARG (0.73) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL5468691 | 0.82 | PPARG (0.98) | PPARGRARGRXRAMAPTALDH1A1 | |
| Rosiglitazone SCHEMBL3377103 | 0.82 | PPARG (0.98) | PPARGRARGRXRAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783592-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170283960-A1 | METHOD OF DISCOVERING FLUORO-CONTAINING COMPOUNDS | SHANXI CHEMICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2017-10-05 | — | — | US | disclosed |
| US-20160051688-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | UNIV INDIANA RES & TECH CORP (US) | 2016-02-25 | — | — | US | disclosed |
| US-20150320871-A1 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity | UNIV INDIANA RES & TECH CORP (US) | 2015-11-12 | — | — | US | disclosed |
| US-9145451-B2 | Glucagon superfamily peptides exhbiting G protein coupled receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-29 | — | — | US | disclosed |
| US-9127088-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150004144-A1 | DIFFERENTIATION INTO BROWN ADIPOCYTES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | MARCADIA BIOTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | THE BURNHAM INSTITUTE (US) | 2010-01-21 | — | — | US | disclosed |
| US-20030092742-A1 | Process for the preparation of thiazolidinedione derivatives | SMITHKLINE BEECHAM P.L.C. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | GCGR, GLP1R, GIPR | PPARG 155/4885RARG 771/4885RXRA 825/4885 |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | PPARG 50/4885RARG 704/4885RXRA 1062/4885 |
| US-20030092742-A1 | Process for the preparation of thiazolidinedione derivatives | NAT1, CYP2F1, TALDO1 | PPARG 528/4885RARG 1932/4885RXRA 1769/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | PPARG 85/4885RARG 474/4885RXRA 822/4885 |
| US-20150320871-A1 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity | GIPR, GLP1R, GCGR | PPARG 32/4885RARG 297/4885RXRA 161/4885 |
| US-20160051688-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | GCGR, GLP1R, GIPR | PPARG 135/4885RARG 863/4885RXRA 1041/4885 |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | GIPR, GLP1R, GCGR | PPARG 32/4885RARG 297/4885RXRA 161/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | PPARG 45/4885RARG 744/4885RXRA 905/4885 |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | APAF1, F11, SERPINB1 | PPARG 4749/4885RARG 4684/4885RXRA 3848/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | PPARG 60/4885RARG 390/4885RXRA 847/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | PPARG 86/4885RARG 330/4885RXRA 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.